Pharmacokinetics and tissue concentrations of azithromycin in ball pythons (Python regius)

American Journal of Veterinary Research

Volumn 64, Issue 2, 2003, Pages 225-228

  Coke, Rob L ^a,b   Hunter, Robert P ^a   Isaza, Ramiro ^a   Koch, David E ^a   Gotley, Marie A ^a   Carpenter, James W ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b San Antonio Zoo   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BEUTHANASIA D; PHENOBARBITAL; PHENYTOIN; TELAZOL;

ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CLEARANCE; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; SNAKE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; BOIDAE; CROSS-OVER STUDIES; FEMALE; MALE; TISSUE DISTRIBUTION;

ANIMALIA; PYTHON REGIUS; PYTHONIDAE; SERPENTES;

EID: 12244265501     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2003.64.225     Document Type: Article

References (31)

1. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 1990;25(suppl A):49-60.
2. Champney WS, Burdine R. Azithromycin And clarithromycin inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 1998;36:119-123.
3. Girard AE, Girard D, English AR, et al. Pharmacokinetics and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended hall lilc and cxcellent tissue distribution. Antimicrob Agents Chemother 1987;31:1948-1954.
4. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-02, 993), a new 15-membered-ring macrolicle with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-1947.
5. Anderson SL, Berman J, Kuschner R, et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995;123:771-773.
6. Chang HR. The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Int J STD AIDS 1996;7 (suppll):18-22.
7. Dever LL, Jorgensen JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993;37:1704-1706.
8. Hyde TB, Gilbert M, Schwartz SB, et at. Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia. J Infect Dis 2001;183:907-912.
9. Ikerd TR, Koletar SL. In-vitro activity of ciprofloxacin, temafloxacin, azithromycin, clarithromycin and metronidazole against Giardia lamblia. J Antimicrob Chemother 1993;31:615-617.
10. Niki Y, Kimura M, Miyashita N, et al. In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against Chlamydia. Antimicrob Agents Chemother 1994;38:2296-2299.
11. Rehg J. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. J Infect Dis 1994;170:934-938.
12. Van der Heyden N. New strategies in the treatment of avian mycobacteriosis. Semin Avian Exot Pet Med 1997;6:25-33.
13. Hunter RF, Lynch MJ, Ericson JE et al. Pharmacokinetics, oral bioavailability, and tissue distribution of azithromycin in cats. J Vet Pharmacol Ther 1995;18:38-46.
14. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Alled 1991;91:5-11.
15. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995;23:S10-S14.
16. Girard AE, Cimochowski CR, Faiella JA. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J Antimicrob Chemother 1996; 37(suppl C):9-19.
17. de Vosjoli P, Klingenberg R, Barker D, et al. The ball python manual. Santee, Calif: Advanced Vivarium Systems, 1997;76.
18. Fouda HG, Shepard RM, Ferraina RA, et al. Atmospheric pressure HPLC/MS/MS identification of azithromycin rat biliary metabolites, in Proceedings. 38th Am See Mass Spectrom Conf Allied Topics, 1990.
19. Gibaldi M, Perrier P. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;409-417.
20. Riviere JE. Comparative pharmaco kinetics: principles, techniques, and applications. Ames, Iowa: Iowa State University Press, 1999;327.
21. Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co, 2002,2739-2751.
22. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(suppl A):73-82.
23. Boothe DM. Small animal clinical pharmacology and therapeutics. Philadelphia: WB Saunders Co, 2001;806.
24. Hilf M, Swanson D, Wagner R, et al. Pharmacokinetics of piperacillin in blood pythons (Python curtus) and in vitro evaluation of efficacy against aerobic gram-negative bacteria. J Zoo Wildl Med 1991;22:199-203.
25. Johnson JH, Jensen JM, Brumbaugh GW, et al. Amikacin pharmacokinetics and the effects of ambient temperature on the dosage regimen in ball pythons (Python regius). J Zoo Wildl Med 1997;28:80-88.
26. Starck JM, Beese K. Structural flexibility of the intestine of Burmese python in response to feeding. J Exp Biol 2001;204:325-335.
27. Secor SM, Diamond J. Determinants of the post-feeding metabolic response of Burmese pythons, Python molurus. Physiol Zool 1997;70:202-212.
28. Starck JM, Beese K. Structural flexibility of the small intestine and liver of garter snakes in response to feeding and fasting. J Exp Biol 2002;205:1377-1388.
29. Cooper JE. Bacteria. In: Cooper JE, Jackson OF, eds. Diseases of the reptilia. Vol 1. London: Academic Press Inc, 1981;165-191.
30. Jones K, Felmingham D, Ridgway G. In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. Drugs Exp Clin Res 1988;14:613-615.
31. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-2275.